Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US panel to weigh continued sale of propoxyphene

This article was originally published in Scrip

Executive Summary

The USFDA's anaesthetic and life support drugs and drug safety/risk management advisory panels will meet on January 30th to consider whether propoxyphene-containing products (such as Xanodyne's Darvocet, Darvon and generics) should remain on the market. The committees will discuss the safety and efficacy data for all products containing the analgesic ingredient, including combination drugs, and whether regulatory action is appropriate. In 2006 the US consumer group Public Citizen petitioned the FDA to begin a phased withdrawal of propoxyphene-containing medicines owing to safety issues. The drug has a cardiotoxic metabolite and has been associated with more than 2,000 accidental deaths in the US since 1981, the group said. Last year Public Citizen sued the FDA for failing to act on the petition.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007418

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel